TL;DR — NR is a legitimate NAD+ precursor with human RCT data. TNiC standardizes on NMN for stack integration, but NR is defensible if your physician prefers it or you already respond. Never combine high-dose NR + NMN without oversight.
NR vs NMN — same destination, different molecule
Both nicotinamide riboside (NR) and NMN feed the NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → salvage pathway:
`
NR → NMN → NAD+ → SIRT1/3, PARP, CD38 balance
`
NR requires one enzymatic step (NRK) before becoming NMN. In practice, both raise NAD+ metabolites in humans — the debate is dose economics, stack integration, and individual response — not whether NAD+ restoration works.
Martens 2018 (PMID 29599478): NR elevated whole-blood NAD+ in healthy middle-aged and older adults (Nature Communications RCT). Trammell 2016 and subsequent RCTs confirm human PK. Compare head-to-head in NMN vs NR.
When to choose NR over NMN
| Choose NR when | Choose NMN when |
|---|---|
| Physician already prescribed NR | Running TNiC Mito or SIRT1 stacks |
| Prior NR trial with confirmed NAD+ rise | Matching Igarashi 250 mg protocol |
| Trusted NR-Cl brand with batch COA | Stack Architect native integration |
NR or NMN for your stack?
Physician prescribed NR or you have week-4 NAD+ proof on NR?
Continue NR — log in Lab Hub; do not add NMN without clearance
node | Running TNiC NAD+ stack (Mito / Starter / Hybrid)?
Default NMN 250 mg AM — NMN module
Run the NICO Starter Questionnaire → compare table → pick one precursor only
Combining 500 mg+ NR with 500 mg+ NMN → physician oversight required
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Evidence summary
| Study | Molecule | Dose | Outcome | Tier |
|---|---|---|---|---|
| Martens 2018 | NR | 1000 mg | ↑ whole-blood NAD+ | A |
| Trammell 2016 | NR | 100–1000 mg | ↑ NAD+ metabolites | A |
| Igarashi 2022 | NMN | 250 mg | ↑ NAD+, functional signal | A |
← Swipe for more columns →
Honest framing: Tier A for NAD+ elevation. No human longevity endpoint trial for either precursor. Mouse data supports both.
Where NR disappoints
- NAD+ goes up; function often doesn't. NR has more human RCTs than NMN — and that larger literature is sobering: several well-run trials raised NAD+ reliably but showed no improvement in insulin sensitivity, blood pressure, mitochondrial function, or body composition. The biomarker moves; the outcome frequently doesn't. - You may feel nothing. Because the functional payoff is inconsistent, many people see a NAD+ rise on labs and no subjective change — that's a legitimate result, not a dosing error. - It's redundant with NMN. NR converts to NMN en route to NAD+ — running both is paying twice for one pathway.
What would change this grade. NR is A for raising NAD+, not for clinical benefit. It would earn an outcome-level grade with a human trial showing a hard functional endpoint improves — the current, comparatively large NR trial base makes the absence of such a result notable. It would fall toward B for practical use if further trials keep showing NAD+ rises without functional gains.
Dosing protocol (NR)
| Parameter | Recommendation |
|---|---|
| Dose | 300–1000 mg/day (trial-matched) |
| Form | Nicotinamide riboside chloride (NR-Cl) |
| Timing | AM, consistent daily |
| Duration | Minimum 12 weeks before judging |
| Retest | NAD+ index at week 4 |
See the NAD+ supplement buyer guide for COA demands and red flags.
Stack integration on TNiC
NR is not a native compound ID in Stack Architect — substitute manually if you chose NR:
- Build your preset in Stack Architect
- Swap NMN for NR in your personal log (Lab Hub notes)
- Keep PM resveratrol pairing if running NAD+ Mito Stack
Shop verification for NR
If you chose NR, use the Protocol Shop NR pick — same COA checklist as NMN, different molecule verification (NR-Cl identity, not β-NMN).
Full evidence comparison
NMN vs NR compare tableMonitoring
NR and NMN are judged on the same readout: does whole-blood NAD+ actually rise, and does function follow?
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| NAD+ index | 80–100 | Baseline, 4 wk, 12 wk | No rise by week 4 → verify product identity (NR-Cl) and dose |
| Subjective energy | ≥7/10 morning | Daily log | Flat despite NAD+ rise → audit sleep and PM resveratrol pairing |
| Resting heart rate | ↓2–5 bpm trend | Weekly wearable | Rising → physician review |
| Fasting glucose | <100 mg/dL | 3 months | Reduce dose if symptomatic hypoglycemia |
← Swipe for more columns →
NAD+ index
55–70
Morning energy
5–6/10
Resting HR
65–72 bpm
NAD+ index
80+
Morning energy
7–8/10
Resting HR
60–68 bpm
Safety, red flags, and contraindications
- Well tolerated: Human RCTs (Martens 2018, Trammell 2016) report good tolerability at 300–1000 mg/day.
- Do not double-dose precursors: Combining high-dose NR and NMN offers no proven additive benefit and needs physician oversight.
- Methyl donor drain: Long-term high-dose NAD+ precursors can increase nicotinamide methylation — ensure adequate B12, folate, and betaine on 6+ month protocols.
Do not self-start without clearance
- Active chemotherapy or immunotherapy — NAD+ biology interacts with treatment intent; oncologist clearance required
- Pregnancy or breastfeeding — insufficient human safety data
- Combining 500 mg+ NR with 500 mg+ NMN — physician oversight required; do not stack precursors casually
- Unexplained muscle pain worsening on NR — pause and rule out metabolic causes
Who should skip NR
- Anyone already taking NMN — NR converts to NMN; running both is redundant, not additive. - People expecting a felt effect — NR's human trials show a reliable NAD+ rise but inconsistent functional benefit; set expectations accordingly. - Active cancer treatment or pregnancy/breastfeeding — insufficient/uncertain safety; get clearance first.
Works against / redundant with
| Antagonist | Conflict | What to do |
|---|---|---|
| NMN | Same NAD+ endpoint (NR → NMN → NAD+) — stacking both is redundant and needs oversight at high doses | Pick one precursor |
| High-dose niacin | Overlapping NAD+ route plus flush/lipid effects that confound the readout | Don't combine for NAD+ purposes |
| Chronic inflammation / high CD38 | CD38 degrades NAD+ faster than precursors restore it | Address the inflammatory driver first |
Personal results template
My NR results log
| Date | Week | Dose | NAD+ | Energy (1–10) | RHR | Resveratrol PM? | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | No | Baseline |
| YYYY-MM-DD | 4 | 300–500 mg | — | — | — | Yes | Early NAD+ check |
| YYYY-MM-DD | 12 | 300–1000 mg | — | — | — | Yes | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: NAD+ index ≥80 OR energy ↑2 points + RHR ↓3 bpm - Plateau: NAD+ up but flat energy → confirm PM resveratrol + sleep audit before adding anything - Adverse: Muscle pain, glucose crashes, insomnia spike → pause and consult
Track NAD+ on NR
Log NAD+ index the same way whether you run NR or NMN — the readout is identical.
Open Labs hubReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.